Gensight Biologics SA Stock
€0.37
Your prediction
Gensight Biologics SA Stock
Pros and Cons of Gensight Biologics SA in the next few years
Pros
Cons
Performance of Gensight Biologics SA vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Gensight Biologics SA | -1.080% | 2.650% | 12.366% | -42.500% | -16.930% | -95.167% | -69.333% |
India Globalization Capital | -7.040% | -10.204% | -22.807% | -25.424% | 0.763% | -79.847% | -72.391% |
Celsion Corp. | - | 1.508% | 11.602% | -1.942% | 69.748% | -91.984% | -95.637% |
Protara Therapeutics Inc. | 6.210% | 11.765% | -7.065% | 6.211% | 1.183% | -71.736% | - |
Comments
News
GenSight Biologics Reports Cash Position as of June 30, 2024, and Provides Business Update
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
GenSight Biologics Launches Newsletter for Retail Investors
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
GenSight Biologics Renegotiates Financial Obligations and Provides Operational Updates
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal